These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 23141781)
1. Genetic analysis of the principal genes related to prostate cancer: a review. Alvarez-Cubero MJ; Saiz M; Martinez-Gonzalez LJ; Alvarez JC; Lorente JA; Cozar JM Urol Oncol; 2013 Nov; 31(8):1419-29. PubMed ID: 23141781 [TBL] [Abstract][Full Text] [Related]
2. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Beuten J; Gelfond JA; Franke JL; Shook S; Johnson-Pais TL; Thompson IM; Leach RJ Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):588-99. PubMed ID: 20086112 [TBL] [Abstract][Full Text] [Related]
3. Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk. Alvarez-Cubero MJ; Pascual-Geler M; Martinez-Gonzalez LJ; Expósito Ruiz M; Saiz M; Cozar JM; Lorente JA Urol Oncol; 2016 Oct; 34(10):431.e1-8. PubMed ID: 27318894 [TBL] [Abstract][Full Text] [Related]
5. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Rennert H; Zeigler-Johnson CM; Addya K; Finley MJ; Walker AH; Spangler E; Leonard DG; Wein A; Malkowicz SB; Rebbeck TR Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):949-57. PubMed ID: 15824169 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Xu J; Zheng SL; Carpten JD; Nupponen NN; Robbins CM; Mestre J; Moses TY; Faith DA; Kelly BD; Isaacs SD; Wiley KE; Ewing CM; Bujnovszky P; Chang B; Bailey-Wilson J; Bleecker ER; Walsh PC; Trent JM; Meyers DA; Isaacs WB Am J Hum Genet; 2001 Apr; 68(4):901-11. PubMed ID: 11254448 [TBL] [Abstract][Full Text] [Related]
7. Prognostic role of genetic biomarkers in clinical progression of prostate cancer. Alvarez-Cubero MJ; Martinez-Gonzalez LJ; Saiz M; Carmona-Saez P; Alvarez JC; Pascual-Geler M; Lorente JA; Cozar JM Exp Mol Med; 2015 Aug; 47(8):e176. PubMed ID: 26251261 [TBL] [Abstract][Full Text] [Related]
8. Involvement of the RNAse L gene in prostate cancer. Kieffer N; Schmitz M; Scheiden R; Nathan M; Faber JC Bull Soc Sci Med Grand Duche Luxemb; 2006; (1):21-8. PubMed ID: 16869093 [TBL] [Abstract][Full Text] [Related]
9. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Robbins CM; Hernandez W; Ahaghotu C; Bennett J; Hoke G; Mason T; Pettaway CA; Vijayakumar S; Weinrich S; Furbert-Harris P; Dunston G; Powell IJ; Carpten JD; Kittles RA Prostate; 2008 Dec; 68(16):1790-7. PubMed ID: 18767027 [TBL] [Abstract][Full Text] [Related]
10. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Noonan-Wheeler FC; Wu W; Roehl KA; Klim A; Haugen J; Suarez BK; Kibel AS Prostate; 2006 Jan; 66(1):49-56. PubMed ID: 16114055 [TBL] [Abstract][Full Text] [Related]
12. ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case-control studies. Xu B; Tong N; Li JM; Zhang ZD; Wu HF Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):270-7. PubMed ID: 20231859 [TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer. Wu YQ; Chen H; Rubin MA; Wojno KJ; Cooney KA Cancer Res; 2001 Dec; 61(24):8651-3. PubMed ID: 11751379 [TBL] [Abstract][Full Text] [Related]
14. MSR1 variants and the risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Hsing AW; Sakoda LC; Chen J; Chokkalingam AP; Sesterhenn I; Gao YT; Xu J; Zheng SL Carcinogenesis; 2007 Dec; 28(12):2530-6. PubMed ID: 17768178 [TBL] [Abstract][Full Text] [Related]
15. Prostate cancer susceptibility genes: many studies, many results, no answers. Nupponen NN; Carpten JD Cancer Metastasis Rev; 2001; 20(3-4):155-64. PubMed ID: 12085959 [TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Suarez BK; Gerhard DS; Lin J; Haberer B; Nguyen L; Kesterson NK; Catalona WJ Cancer Res; 2001 Jul; 61(13):4982-4. PubMed ID: 11431329 [TBL] [Abstract][Full Text] [Related]
17. Association between genetic polymorphisms of macrophage scavenger receptor 1 gene and risk of prostate cancer in the health professionals follow-up study. Chen YC; Giovannucci E; Kraft P; Hunter DJ Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):1001-3. PubMed ID: 18398045 [TBL] [Abstract][Full Text] [Related]
18. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men. Takahashi H; Lu W; Watanabe M; Katoh T; Furusato M; Tsukino H; Nakao H; Sudo A; Suzuki H; Akakura K; Ikemoto I; Asano K; Ito T; Wakui S; Muto T; Hano H Int J Cancer; 2003 Nov; 107(2):224-8. PubMed ID: 12949798 [TBL] [Abstract][Full Text] [Related]